Current evidence for antithrombotic therapy after peripheral vascular interventions

Current Vascular Pharmacology

Volumn 11, Issue 4, 2013, Pages 507-513

  Saha, Sibu P ^a   Whayne Jr , Thomas F ^a   Mukherjee, Debabrata ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Anticoagulation; Aspirin; Peripheral arterial disease; Platelet inhibitors; Thrombin inhibitors

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; CILOSTAZOL; CLOPIDOGREL; COUMARIN; D DIMER; DABIGATRAN; DEXTRAN 40; DIPYRIDAMOLE; ENOXAPARIN; EPTIFIBATIDE; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; RIVAROXABAN; SEROTONIN; THIENOPYRIDINE DERIVATIVE; THROMBIN ANTITHROMBIN COMPLEX; TICAGRELOR; TIROFIBAN; WARFARIN;

ACUTE CORONARY SYNDROME; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); CORONARY ARTERY BYPASS SURGERY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; NONHUMAN; PEPTIC ULCER; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REVASCULARIZATION; REVIEW; THROMBOSIS;

ANTICOAGULANTS; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; FACTOR XA; FIBRINOLYTIC AGENTS; HUMANS; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; THROMBOSIS; VASCULAR SURGICAL PROCEDURES;

EID: 84882788251     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161111311040014     Document Type: Review

References (55)

1. Gillum RF. Peripheral arterial occlusive disease of the extremities in the United States: hospitalization and mortality. Am Heart J 1990; 120 (6 Pt 1): 1414-8.
2. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317-24.
3. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975; 56: 624-32.
4. Majerus PW. Arachidonate metabolism in vascular disorders. J Clin Invest 1983; 72: 1521-5.
5. Patrono C, Baigent C, Hirsh J, et al. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl): 199S-233S.
6. Wong PF, Chong LY, Mikhailidis DP, et al. Antiplatelet agents for intermittent claudication. Cochrane Database Syst Rev 2011; 11: CD001272.
7. Dorffler-Melly J, Koopman MM, Prins MH, et al. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev 2005; (1): CD002071.
8. Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-7.
9. Biondi-Zoccai G, Lotrionte M, Agostoni P, et al. Adjusted indirect comparison meta-analysis of prasugrel vs. ticagrelor for patients with acute coronary syndromes. Int J Cardiol 2011; 150: 325-31.
10. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel vs. clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.
11. Kowalczyk M, Banach M, Mikhailidis DP, et al. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors? Med Sci Monit 2009; 15: MS24-30.
12. Held C, Asenblad N, Bassand JP, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 2011; 57: 672-84.
13. Bhatt DL. Prasugrel in clinical practice. N Engl J Med 2009; 361: 940-2.
14. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor vs. clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120: 2577-85.
15. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38: 92-9.
16. Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol 2011; 57: 1251-63.
17. Aster RH. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest 2005; 127 (2 Suppl): 53S-59S.
18. Born G, Patrono C. Antiplatelet drugs. Br J Pharmacol 2006; 147 (Suppl 1): S241-51.
19. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
20. Weyrich AS, Denis MM, Kuhlmann-Eyre JR, et al. Dipyridamole selectively inhibits inflammatory gene expression in plateletmonocyte aggregates. Circulation 2005; 111: 633-42.
21. Katakami N, Kim YS, Kawamori R, et al. The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial. Circulation 2010; 121: 2584-91.
22. Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010; 9: 959-68.
23. Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. Br J Haematol 2008; 141: 757-63.
24. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran vs. warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
25. Shammas NW. Complications in peripheral vascular interventions: emerging role of direct thrombin inhibitors. J Vasc Interv Radiol 2005; 16 (2 Pt 1): 165-71.
26. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban vs. warfarin in non-valvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.
27. Turpie AG, Lassen MR, Eriksson BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011; 105: 444-53.
28. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban vs. warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.
29. Smout JD, Mikhailidis DP, Shenton BK, et al. Combination antiplatelet therapy in patients with peripheral vascular bypass grafts. Clin Appl Thromb Hemost 2004; 10: 9-18.
30. Cheshire NJ, Wolfe JH, Barradas MA, et al. Smoking and plasma fibrinogen, lipoprotein (a) and serotonin are markers for postoperative infrainguinal graft stenosis. Eur J Vasc Endovasc Surg 1996; 11: 479-86.
31. Thompson JF, Mullee MA, Bell PR, et al. Intraoperative heparinisation, blood loss and myocardial infarction during aortic aneurysm surgery: a Joint Vascular Research Group study. Eur J Vasc Endovasc Surg 1996; 12: 86-90.
32. Gram J, Mercker S, Bruhn HD. Does protamine chloride neutralize low molecular weight heparin sufficiently? Thromb Res 1988; 52: 353-9.
33. van Veen JJ, Maclean RM, Hampton KK, et al. Protamine reversal of low molecular weight heparin: clinically effective? Blood Coagul Fibrinolysis 2011; 22: 565-70.
34. Norgren L. Can low molecular weight heparin replace unfractionated heparin during peripheral arterial reconstruction? An open label prospective randomized controlled trial. J Vasc Surg 2004; 39: 977-84.
35. Goldhaber SZ, Manson JE, Stampfer MJ, et al. Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study. Lancet 1992; 340: 143-5.
36. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. Lancet 2000; 355: 346-51.
37. Hess H, Mietaschk A, Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Lancet 1985; 1: 415-9.
38. Collaborative overview of randomised trials of antiplatelet therapy-II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration. BMJ 1994; 308: 159-68.
39. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin vs. aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-17.
40. Belch JJ, Dormandy J, Biasi GM, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg 2010; 52: 825-33.
41. Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997; 26: 517-38.
42. Katz SG, Kohl RD. Does dextran 40 improve the early patency of autogenous infrainguinal bypass grafts? J Vasc Surg 1998; 28: 23-6; discussion 26-7.
43. Arfvidsson B, Lundgren F, Drott C, et al. Influence of coumarin treatment on patency and limb salvage after peripheral arterial reconstructive surgery. Am J Surg 1990; 159: 556-60.
44. Sarac TP, Huber TS, Back MR, et al. Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure. J Vasc Surg 1998; 28: 446-57.
45. Johnson WC, Williford WO. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg 2002; 35: 413-21.
46. Geraghty AJ, Welch K. Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery. Cochrane Database Syst Rev 2011; (6): CD000536.
47. Minar E, Ahmadi A, Koppensteiner R, et al. Comparison of effects of high-dose and low-dose aspirin on restenosis after femoropopliteal percutaneous transluminal angioplasty. Circulation 1995; 91: 2167-73.
48. Ranke C, Creutzig A, Luska G, et al. Controlled trial of high-vs. low-dose aspirin treatment after percutaneous transluminal angioplasty in patients with peripheral vascular disease. Clin Investig 1994; 72: 673-80.
49. Weichert W, Meents H, Abt K, et al. Acetylsalicylic acid-reocclusion--prophylaxis after angioplasty (ARPA-study). A randomized double-blind trial of two different dosages of ASA in patients with peripheral occlusive arterial disease. VASA 1994; 23: 57-65.
50. Cassar K, Ford I, Greaves M, et al. Randomized clinical trial of the antiplatelet effects of aspirin-clopidogrel combination vs. aspirin alone after lower limb angioplasty. Br J Surg. 2005; 92: 159-65.
51. Cassar K, Bachoo P, Ford I, et al. Clopidogrel has no effect on Ddimer and thrombin-antithrombin III levels in patients with peripheral arterial disease undergoing peripheral percutaneous transluminal angioplasty. J Vasc Surg 2005; 42: 252-8.
52. Milani RV. Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy? Catheter Cardiovasc Interv 2009; 74 (Suppl 1): S7-S11.
53. Visona A, Tonello D, Zalunardo B, et al. Antithrombotic treatment before and after peripheral artery percutaneous angioplasty. Blood Transfus 2009; 7: 18-23.
54. Brumberg RS, Back MR, Armstrong PA, et al. The relative importance of graft surveillance and warfarin therapy in infrainguinal prosthetic bypass failure. J Vasc Surg 2007; 46: 1160-6.
55. Sobel M, Verhaeghe R. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl): 815S-43S.